Display options
Cite
Nevens F, Gustot T, Laterre PF, et al. A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation. JHEP Rep. 2021;3(4):100291doi: 10.1016/j.jhepr.2021.100291.
Nevens, F., Gustot, T., Laterre, P. F., Lasser, L. L., Haralampiev, L. E., Vargas, V., Lyubomirova, D., Albillos, A., Najimi, M., Michel, S., Stoykov, I., Gordillo, N., Vainilovich, Y., Barthel, V., Clerget-Chossat, N., & Sokal, E. M. (2021). A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation. JHEP reports : innovation in hepatology, 3(4), 100291. https://doi.org/10.1016/j.jhepr.2021.100291
Nevens, Frederik, et al. "A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation." JHEP reports : innovation in hepatology vol. 3,4 (2021): 100291. doi: https://doi.org/10.1016/j.jhepr.2021.100291
Nevens F, Gustot T, Laterre PF, Lasser LL, Haralampiev LE, Vargas V, Lyubomirova D, Albillos A, Najimi M, Michel S, Stoykov I, Gordillo N, Vainilovich Y, Barthel V, Clerget-Chossat N, Sokal EM. A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation. JHEP Rep. 2021 Apr 18;3(4):100291. doi: 10.1016/j.jhepr.2021.100291. eCollection 2021 Aug. PMID: 34169246; PMCID: PMC8207211.
Copy Download .nbib Format: NLM
Share it on

JHEP Rep. 2021 Apr 18;3(4):100291. doi: 10.1016/j.jhepr.2021.100291. eCollection 2021 Aug.

A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation.

JHEP reports : innovation in hepatology

Frederik Nevens, Thierry Gustot, Pierre-François Laterre, Luc L Lasser, Lyudmil E Haralampiev, Victor Vargas, Desislava Lyubomirova, Agustin Albillos, Mustapha Najimi, Sébastien Michel, Ivaylo Stoykov, Noelia Gordillo, Yelena Vainilovich, Virginie Barthel, Nathalie Clerget-Chossat, Etienne M Sokal

Affiliations

  1. Department of Gastroenterology and Hepatology, University Hospitals, KU Leuven, Belgium.
  2. Department of Gastroenterology and Hepato-Pancreatology, C.U.B. Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.
  3. Intensive Care Unit, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium.
  4. Gastroenterology Clinic, CHU Brugmann, Brussels, Belgium.
  5. Department of Hepatogastroenterology, CHU Brugmann, Brussels, Belgium.
  6. Department of Internal Diseases, Multiprofile Hospital for Active Treatment (MEDICA), Ruse, Bulgaria.
  7. Liver Unit, Hospital Vall d'Hebron, Universitat Autònoma Barcelona, CIBERehd, Barcelona, Spain.
  8. Department of Clinical Gastroenterology with Hepatology, Gastroenterology Clinic, University Multiprofile Hospital for Active Treatment "Georgi Stranski", Pleven, Bulgaria.
  9. Gastroenterology and Hepatology, University Hospital Ramón y Cajal, Madrid, Spain.
  10. UCLouvain, Institute of Experimental and Clinical Research (IREC), Laboratory of Pediatric Hepatology and Cell Therapy (PEDI), Brussels, Belgium.
  11. Promethera Biosciences, Mont-Saint-Guibert, Belgium.
  12. Cliniques Universitaires Saint-Luc, UCLouvain, Pediatric Hepatology & Gastroenterology Unit, Brussels, Belgium.

PMID: 34169246 PMCID: PMC8207211 DOI: 10.1016/j.jhepr.2021.100291

Abstract

BACKGROUND & AIMS: Human allogeneic liver-derived progenitor cells (HALPC, HepaStem®; Promethera Biosciences, Mont-Saint-Guibert, Belgium) are an advanced therapy medicinal product that could potentially alleviate systemic inflammation and ameliorate liver function in patients with acute-on-chronic liver failure (ACLF) or acute decompensation of cirrhosis (AD).

METHODS: This open-label phase II study was conducted in 9 centres in Belgium, Spain, and Bulgaria between 2016 and 2019. The primary objective was to assess the safety of HALPC therapy up to Day 28 and the secondary objectives were to assess its safety and preliminary efficacy up to Month 3.

RESULTS: The 24 treated patients (mean age: 51 years) were mostly male with an alcoholic cirrhosis. On pre-infusion Day 1, 15 patients had ACLF and 9 patients had AD. Two of the 3 initial patients treated with high HALPC doses (∼5×10

CONCLUSIONS: The treatment of patients with ACLF or AD with up to 2 doses of 1.2×10

CLINICAL TRIALS REGISTRATION: EudraCT 2016-001177-32.

LAY SUMMARY: Patients with liver cirrhosis may suffer from the rapid onset of organ failure or multiple organ failure associated with a high risk of death in the short term. This clinical study of 24 patients suggests that an advanced therapy based on the intravenous infusion of low doses of human allogeneic liver-derived progenitor cells is safe and supports the next phase of clinical development of this type of therapy.

© 2021 The Author(s).

Keywords: ACLF, acute-on-chronic liver failure; AD, acute decompensation of liver cirrhosis; AE, adverse event; AESI, AE of special interest; ATMP, advanced therapy medicinal product; Alcoholic liver disease; BW, body weight; CRP, C-reactive protein; EASL-CLIF, European Association for the Study of Chronic Liver Failure; HALPC, human allogeneic liver-derived progenitor cells; INR, international normalised ratio; Liver regenerative medicine; MELD, model for end-stage liver disease; MSC, mesenchymal stem cells; SAE, serious AE; SAS, safety analysis set; SUSAR, suspected unexpected serious adverse reaction; Stem cell; TEG, thromboelastography; TGT, thrombin generation test; i.v., intravenous

Conflict of interest statement

NC-C, IS, NG, YV, SM, and VB are employees of Promethera Biosciences. MN is a founder, patent holder, and consultant of Promethera Biosciences and employee of UCLouvain. ES is a founder, patent holder

References

  1. N Engl J Med. 2020 May 28;382(22):2137-2145 - PubMed
  2. PLoS One. 2012;7(8):e42819 - PubMed
  3. Cell Transplant. 2007;16(7):717-28 - PubMed
  4. J Crit Care. 2018 Feb;43:54-60 - PubMed
  5. Front Immunol. 2019 Mar 19;10:476 - PubMed
  6. Ann Hepatol. 2013 Sep-Oct;12(5):713-24 - PubMed
  7. Stem Cells Dev. 2015 Oct 1;24(19):2269-79 - PubMed
  8. Nat Rev Dis Primers. 2016 Jun 09;2:16041 - PubMed
  9. Transplantation. 2017 Aug;101(8):1845-1851 - PubMed
  10. Stem Cells. 2018 Nov;36(11):1778-1788 - PubMed
  11. J Immunol Res. 2019 Sep 12;2019:8250584 - PubMed
  12. Gastroenterology. 2013 Jun;144(7):1426-37, 1437.e1-9 - PubMed
  13. Cell Transplant. 2012;21(10):2241-55 - PubMed
  14. Stem Cells Transl Med. 2012 Oct;1(10):725-31 - PubMed
  15. Trends Mol Med. 2019 Feb;25(2):149-163 - PubMed
  16. Hepatology. 2017 Jul;66(1):209-219 - PubMed
  17. Transplantation. 2019 Sep;103(9):1903-1915 - PubMed
  18. Stem Cells Transl Med. 2017 Jun;6(6):1445-1451 - PubMed
  19. Stem Cell Res Ther. 2020 Feb 7;11(1):51 - PubMed
  20. Hepatol Int. 2015 Jul;9(3):355-9 - PubMed
  21. J Hepatol. 2018 Aug;69(2):406-460 - PubMed
  22. Hepatology. 2005 Mar;41(3):553-8 - PubMed
  23. Stem Cells Int. 2017;2017:2679518 - PubMed
  24. Hepatology. 2016 Dec;64(6):2165-2172 - PubMed
  25. Lancet. 2008 May 10;371(9624):1579-86 - PubMed
  26. Gut. 2010 Nov;59(11):1561-9 - PubMed
  27. Hepatobiliary Surg Nutr. 2018 Oct;7(5):331-344 - PubMed
  28. Hematology Am Soc Hematol Educ Program. 2015;2015:243-9 - PubMed
  29. Sci Rep. 2016 May 05;6:25487 - PubMed
  30. Stem Cell Res Ther. 2017 Jun 5;8(1):131 - PubMed
  31. Gastroenterology. 2008 May;134(5):1360-8 - PubMed
  32. Hepatology. 2013 Mar;57(3):1153-62 - PubMed
  33. Stem Cells. 2014 Sep;32(9):2430-42 - PubMed
  34. Crit Care Med. 2017 Oct;45(10):1616-1624 - PubMed
  35. Hepatology. 2015 Jul;62(1):232-42 - PubMed
  36. Gut. 2019 Oct;68(10):1872-1883 - PubMed
  37. J Hepatol. 2020 Apr;72(4):688-701 - PubMed
  38. Hepatology. 2019 May;69(5):2150-2163 - PubMed

Publication Types